Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995415 | 1.00 | KDM4E (0.44) | KDM4EPKMUSP30GPR119NAMPT | |
| SCHEMBL28932758 | 1.00 | KDM4E (0.44) | KDM4EPKMUSP30GPR119NAMPT | |
| SCHEMBL28871313 | 0.83 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL28871312 | 0.83 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL28871317 | 0.83 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL8260058 | 0.80 | NR1H2 (0.39) | KDM4EGPR119NAMPTMAPK1 | |
| SCHEMBL28302848 | 0.78 | KMT2A (0.39) | MEN1KMT2A | |
| SCHEMBL136257 | 0.77 | NR1H2 (0.41) | KDM4EGPR119NAMPTMAPK1 | |
| SCHEMBL5116359 | 0.76 | KDM4E (0.58) | KDM4EPKMUSP30GPR119MEN1 | |
| SCHEMBL14390228 | 0.76 | KDM4E (0.58) | KDM4EPKMUSP30GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-109790116-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11260049-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-3515887-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
| US-10588891-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | KDM4E 1390/4885PKM 1349/4885USP30 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.